| Source: |
Morgans , A K , Chehrazi-Raffle , A , Niazi , T , Shore , N D , Ross , A E , Røder , A , Gomes , A J , Supiot , S , Barthélémy , P , Hatano , K , Ruiz , C B C , Yoshida , S , Herrera-Imbroda , B , Gratton , M , Gschwend , J E , Hope , T A , Joensuu , H , Kuss , I , Le Berre , M-A , Dimova-Dobreva , M & Fizazi , K 2025 , ' Darolutamide plus androgen-deprivation therapy .... |
| Description: |
Patients with prostate cancer treated with radiotherapy (RT) or radical prostatectomy (RP) as primary therapy may develop biochemical recurrence (BCR), which requires effective treatment to delay disease progression. The ARASTEP study (NCT05794906) aims to determine whether the addition of darolutamide to androgen-deprivation therapy (ADT) improves radiologic progression-free survival (rPFS) using prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) compared with placebo plus ADT in patients with high-risk BCR. Approximately 970 patients from 243 sites globally will receive either darolutamide 600 mg or placebo twice daily, both with ADT, for 24 months or until disease progression, unacceptable toxicity, or withdrawal of consent. Eligible patients will have been treated by primary RT or RP ± adjuvant RT (ART) or salvage RT (SRT), and present with high-risk BCR (prostate-specific antigen [PSA] doubling time 150 ng/dL, and Eastern Cooperative Oncology Group performance status 0/1. The primary endpoint is rPFS using PSMA PET/CT, with secondary endpoints including metastasis-free survival, time to castration-resistant prostate cancer, overall survival, quality of life, and safety. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT05794906. |